These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24748646)

  • 1. HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.
    Núñez C; Cénit MC; Alvarez-Lafuente R; Río J; Fernández-Arquero M; Arroyo R; Montalbán X; Fernández O; Oliver-Martos B; Leyva L; Comabella M; Urcelay E
    J Med Genet; 2014 Jun; 51(6):395-400. PubMed ID: 24748646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis.
    Link J; Lundkvist Ryner M; Fink K; Hermanrud C; Lima I; Brynedal B; Kockum I; Hillert J; Fogdell-Hahn A
    PLoS One; 2014; 9(3):e90479. PubMed ID: 24608124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
    Jungedal R; Lundkvist M; Engdahl E; Ramanujam R; Westerlind H; Sominanda A; Hillert J; Fogdell-Hahn A
    Mult Scler; 2012 Dec; 18(12):1775-81. PubMed ID: 22551640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
    Farrell RA; Espasandin M; Lakdawala N; Creeke PI; Worthington V; Giovannoni G
    Mult Scler; 2011 Nov; 17(11):1333-40. PubMed ID: 21685230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
    Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA associations with multiple sclerosis in Greece.
    Kouri I; Papakonstantinou S; Bempes V; Vasiliadis HS; Kyritsis AP; Pelidou SH
    J Neurol Sci; 2011 Sep; 308(1-2):28-31. PubMed ID: 21741664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.
    Buck D; Andlauer TF; Igl W; Wicklein EM; Mühlau M; Weber F; Köchert K; Pohl C; Arnason B; Comi G; Cook S; Filippi M; Hartung HP; Jeffery D; Kappos L; Barkhof F; Edan G; Freedman MS; Montalbán X; Müller-Myhsok B; Hemmer B;
    Mult Scler; 2019 Apr; 25(4):565-573. PubMed ID: 29521573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis.
    Petersen B; Bendtzen K; Koch-Henriksen N; Ravnborg M; Ross C; Sorensen PS;
    Mult Scler; 2006 Jun; 12(3):247-52. PubMed ID: 16764336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
    Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
    Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.
    Weber F; Cepok S; Wolf C; Berthele A; Uhr M; Bettecken T; Buck D; Hartung HP; Holsboer F; Müller-Myhsok B; Hemmer B
    Pharmacogenomics J; 2012 Jun; 12(3):238-45. PubMed ID: 21502966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
    Hegen H; Schleiser M; Gneiss C; Di Pauli F; Ehling R; Kuenz B; Lutterotti A; Berger T; Deisenhammer F
    Mult Scler; 2012 May; 18(5):610-5. PubMed ID: 22013146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.
    Polman CH; Bertolotto A; Deisenhammer F; Giovannoni G; Hartung HP; Hemmer B; Killestein J; McFarland HF; Oger J; Pachner AR; Petkau J; Reder AT; Reingold SC; Schellekens H; Sørensen PS
    Lancet Neurol; 2010 Jul; 9(7):740-50. PubMed ID: 20610349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibodies against interferon β: fluctuation is modest and titre dependent.
    Sominanda A; Hillert J; Fogdell-Hahn A
    Eur J Neurol; 2009 Jan; 16(1):21-6. PubMed ID: 18727672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of a Novel Human Leukocyte Antigen-DQA1*01:02;DRB1*15:01 Mixed Isotype Heterodimer in the Pathogenesis of "Humanized" Multiple Sclerosis-like Disease.
    Kaushansky N; Eisenstein M; Boura-Halfon S; Hansen BE; Nielsen CH; Milo R; Zeilig G; Lassmann H; Altmann DM; Ben-Nun A
    J Biol Chem; 2015 Jun; 290(24):15260-78. PubMed ID: 25911099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.
    Goodin DS; Hurwitz B; Noronha A
    J Int Med Res; 2007; 35(2):173-87. PubMed ID: 17542405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
    Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.
    Hartung HP; Freedman MS; Polman CH; Edan G; Kappos L; Miller DH; Montalbán X; Barkhof F; Petkau J; White R; Sahajpal V; Knappertz V; Beckmann K; Lanius V; Sandbrink R; Pohl C;
    Neurology; 2011 Aug; 77(9):835-43. PubMed ID: 21849647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DQB1*0602 allele shows a strong association with multiple sclerosis in patients in Malaga, Spain.
    Fernández O; Fernández V; Alonso A; Caballero A; Luque G; Bravo M; León A; Mayorga C; Leyva L; de Ramón E
    J Neurol; 2004 Apr; 251(4):440-4. PubMed ID: 15083289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.